The rapid spread of coronavirus has been a wakeup call for many pharmaceutical companies on how quickly they can make vaccines for emerging infectious diseases. Many of them have now embraced expansion strategies through acquisitions and collaborations. Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is working collaboratively with outside partners.
The company says that it is in the process of buying a 40,000 square foot facility in Massachusetts. The intent comes with the need to need to expand its portfolio of immunology candidates, which means the implementation of elaborate research and development functions and more laboratories.
The Need to Take Control over the Speed of Creating Vaccines and Biologics Products
The emergence of COVID-19 a few months and the consequences followed, including massive deaths, but many nations were in a helpless status. Research and pharmaceutical companies, which were also caught unawares, have not identified a single vaccine for the virus. Nonetheless, there are so many studies going on.
The situation demonstrates a level of unpreparedness in the pharmaceutical industry. This is the gap Tonix’s Advanced Development Center intends to fill. With the world having been caught up between hard rock and stone, the company understands the need to control the speed of developing vaccines and biologics products.
The CEO of Tonix, Seth Lederman explains, “This is a significant step that we believe will add to our competitive advantage in responding quickly to emerging infectious diseases utilizing our growing range of vaccine technologies and protein-based therapeutic platforms.’’
Tonix’s partnership with the University of Alberta in Canada
The two have signed an exclusive licensing agreement and research collaboration for three new vaccine candidates expected to prevent Covid-19. The three, TNX-1810, TNX-1820, and TNX-1830, have different individual roles. However, they are also designed to prompt different protein antigens from SARS-CoV-2.
Meanwhile, Tonix continues to add to its already unique portfolio primarily composed of immunology product candidates and the central nervous system (CNS). The former includes vaccines for cancer and autoimmune disease while the latter has those of addiction, neurologic and psychiatric conditions, as well as small molecules and biologics for treating pain.